Science & Technology
Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44EY037156-01
Award Ceiling
$871K
Award Floor
$871K
Close Date
Aug 31, 2027
534 days leftTotal Funding
$871K
Expected Awards
1
Posted Date
Sep 15, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44EY037156-01
Description
SBIR Phase Phase II award: "Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1" awarded to ATSENA THERAPEUTICS, INC. in DURHAM, North Carolina. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $870,675. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.